3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO)

s S675 may define QoS and vary in importance along the care continuum. During the interviews, we used the term “survival” as a generic term indicating the pt is alive, and could include the time during and post treatment. The QoS concept was viewed as simple, meaningful and relevant to discussing treatment decisions. Available data from the phase 3 CheckMate 066 trial comparing NIVO to dacarbazine in advanced MEL can be captured in some dimensions of the QoS concept map based on the demonstration of survival benefit, a manageable safety profile, symptom improvement and QoL maintenance. Data on the economic impact of NIVO are not yet available. Conclusion: The QoS concept map can be a unique and pt-centric means for examining elements contributing to the quality of long-term survival in cancer. Trial data for treatment of pts with advanced MEL with NIVO have the potential to inform domains of this QoS concept map. Preliminary results from trials with NIVO combined with ipilimumab in advanced MEL also suggest the same. Additional studies with economic, longer-term and real-world data are required to refine and validate the QoS map in treatment decision making, as well as to further explore the relationships between the domains forming the QoS framework and the derivation of a metric that factor them into one summary score to determine the value of cancer treatments. Conflict of interest: Advisory Board: E. Nadler has had an advisory board/ consulting role with Lilly and Genentech. Corporate-sponsored Research: A.P. Abernethy’s institution has received research funds from DARA Biosciences, GlaxoSmithKline, Celgene, Helsinn, Dendreon, Kanglaite, Bristol-Myers Squibb, and Pfizer. Other Substantive Relationships: L. Fallowfield has received consultancy payments from Bristol-Myers Squibb for work developing the QoS concept. E. Nadler has received honoraria from Genentech, Lilly, and Pfizer. has been on speakers’ bureau for Lilly, Genentech, and Pfizer. A.P. Abernethy is an employee of Flatiron Health, Inc. has leadership with Flatiron Health, Inc. and athenahealth, Inc. has stock ownership with athenahealth, Inc. has received honoraria from Bristol-Myers Squibb, Helsinn, and Merck. I. Gilloteau is a stockholder of Bristol-Myers Squibb. M. Greaney is an employee of Adelphi Values which provides consultancy services to Bristol-Myers Squibb. A. Gater is an employee of Adelphi Values, a health outcomes agency commissioned by Bristol-Myers Squibb to conduct and analyze findings from this research. L. Orsini and M. Subar are employed by Bristol-Myers Squibb. H. Dastani has employment and stock ownership from Bristol-Myers Squibb. G. Lyman has nothing to disclose.